Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDA) arises at the convergence of genetic alterations in KRAS with a fostering microenvironment shaped by immune cell influx and fibrotic changes; identification of the earliest tumorigenic molecular mediators evokes the proverbial chicken and egg problem. Matrix metalloproteinases (MMP) are key drivers of tumor progression that originate primarily from stromal cells activated by the developing tumor. Here, MMP3, known to be expressed in PDA, was found to be associated with expression of Rac1b, a tumorigenic splice isoform of Rac1, in all stages of pancreatic cancer. Using a large cohort of human PDA tissue biopsies specimens, both MMP3 and Rac1b are expressed in PDA cells, that the expression levels of the two markers are highly correlated, and that the subcellular distribution of Rac1b in PDA is significantly associated with patient outcome. Using transgenic mouse models, coexpression of MMP3 with activated KRAS in pancreatic acinar cells stimulates metaplasia and immune cell infiltration, priming the stromal microenvironment for early tumor development. Finally, exposure of cultured pancreatic cancer cells to recombinant MMP3 stimulates expression of Rac1b, increases cellular invasiveness, and activation of tumorigenic transcriptional profiles.


CONCLUSIONS
MMP3 acts as a coconspirator of oncogenic KRAS in pancreatic cancer tumorigenesis and progression, both through Rac1b-mediated phenotypic control of pancreatic cancer cells themselves, and by giving rise to the tumorigenic microenvironment; these findings also point to inhibition of this pathway as a potential therapeutic strategy for pancreatic cancer.
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 U S A;
Christine
C
Mehner
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 U S A;
Erin
E
Miller
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 U S A;
Davitte
D
Khauv
Department of Pathology, Mayo Clinic, Jacksonville, Florida;
Aziza
A
Nassar
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research;
Ann L
AL
Oberg
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research;
William R
WR
Bamlet
Department of Pathology, Mayo Clinic, Rochester, Minnesota; and.
Lizhi
L
Zhang
Department of Visceral-, Thoracic- and Vascular Surgery, Unikliniken Marburg Und Giessen, Marburg, Germany.
Jens
J
Waldmann
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 U S A;
Evette S
ES
Radisky
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 U S A;
Howard C
HC
Crawford
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 U S A; radisky.derek@mayo.edu.
Derek C
DC
Radisky
D061354:Acinar Cells / Q000201:enzymology / Q000473:pathology; D000230:Adenocarcinoma / Q000201:enzymology* / Q000473:pathology*; D000368:Aged; D000818:Animals; D001706:Biopsy; D063646:Carcinogenesis / Q000473:pathology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008264:Macrophages / Q000473:pathology; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000201:enzymology* / Q000473:pathology*; D011379:Prognosis; D021381:Protein Transport; D013347:Subcellular Fractions / Q000378:metabolism; D020830:rac1 GTP-Binding Protein / Q000378:metabolism*; D018631:ras Proteins
C107953:RAC1 protein, human; D019278:Matrix Metalloproteinase 3; D020830:rac1 GTP-Binding Protein; D018631:ras Proteins